79
Views
4
CrossRef citations to date
0
Altmetric
Editorials

Bioengineered factor Xa as a potential new strategy for hemophilia therapy

Pages 121-123 | Published online: 10 Jan 2014
 

Financial & competing interests disclosure

RM Camire is supported by NIH grants P01 HL-74124 Project 2, R01 HL-88010 and research funding from Pfizer. The author also receives royalties from Pfizer for technology related to FXa. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.